Isolated Bone Marrow Involvement in Diffuse Large B Cell Lymphoma: A Report of Three Cases with Review of Morphological, Immunophenotypic and Cytogenetic Findings

Diffuse large B cell lymphoma (DLBL) comprises a heterogenous entity characterized by the presence of large cells, exhibiting a mature B cell phenotype. The high proliferation rate and aggressive disease remain a therapeutic challenge, but the apparent biological diversity permits a risk-stratification model for prognostic grouping through the International Prognostic Index (IPI). Empirical to this approach is the consideration of cytogenetic data, offering an insight into the pathogenetic events which may underlie neoplastic clonal evolution and disease progression. We describe three cases of DLBL presenting with isolated marrow disease, a rare primary finding in this lymphoma. All three cases showed involvement of blood and bone marrow without evidence of splenic or lymph node involvement on imaging studies. Histological and immunophenotypic findings were similar in all three cases, outlining the phenotypic maturity of this disease. Cytogenetic analysis revealed complex karyotypes in the two cases examined. M-FISH (multicolour fluorescent in situ hybridization) performed on bone marrow from case 1 showed several cryptic translocations not evident on G-banding, including a novel translocation between 2p and 9p, and an unbalanced translocation between 14q and 11q. Cytogenetic analysis in case 2 showed abnormalities involving 7q, 9p at the site of the INK4a gene, and the bcl-2 locus, findings confirmed by M-FISH. These cases serve to highlight the biological and cytogenetic heterogenity of DLBL and emphasize the need for complementary investigations in the characterization of this entity.

[1]  E. Jaffe Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[2]  J. Strauchen Primary bone marrow B-cell lymphoma: report of four cases. , 2003, The Mount Sinai journal of medicine, New York.

[3]  A. Zelenetz,et al.  Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. , 2002, Blood.

[4]  D. Hossfeld E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[5]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[6]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[7]  R. Fonseca,et al.  Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization , 2001, British journal of haematology.

[8]  W. Chan,et al.  New approaches to lymphoma diagnosis. , 2001, Hematology. American Society of Hematology. Education Program.

[9]  M. Dyer,et al.  The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. , 2000, Blood.

[10]  F. Berger,et al.  CDK1 and cyclin A expression is linked to cell proliferation and associated with prognosis in non-Hodgkin's lymphomas. , 1999, Leukemia & lymphoma.

[11]  L. Kearney,et al.  The impact of the new FISH technologies on the cytogenetics of haematological malignancies , 1999, British journal of haematology.

[12]  S. Korsmeyer BCL-2 gene family and the regulation of programmed cell death. , 1995, Cancer research.

[13]  Philippe Dessen,et al.  A database on cytogenetics in haematology and oncology , 1999, Nucleic Acids Res..

[14]  V. Diehl,et al.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.

[15]  R. Gascoyne Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Hematology/oncology clinics of North America.

[16]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[17]  D. Weisenburger,et al.  Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.